In terms of spatial heterogeneity, the proportion and subset distribution of CD8 + T cells vary across tumor regions in different ccRCC patients, with some areas containing up to 80% cytotoxic CD8 + T cells [growth—related oncogene B (GRB), CD57 +]. This evidence concerns the gene CD8A and neoplasm.